Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19605733 | 0.88 | SIGMAR1 (0.50) | SIGMAR1CHRNB2CHRNA4CYP19A1CYP11B1 | |
| SCHEMBL1950016 | 0.83 | SIGMAR1 (0.43) | SIGMAR1CHRNB2CHRNA4 | |
| SCHEMBL30027858 | 0.80 | SIGMAR1 (0.41) | SIGMAR1CHRNB2CHRNA4CYP19A1CYP11B1 | |
| SCHEMBL16031737 | 0.78 | — | — | |
| SCHEMBL4624522 | 0.78 | — | — | |
| SCHEMBL24592357 | 0.73 | CYP11B2 (0.49) | SIGMAR1CHRNB2CHRNA4CYP19A1CYP11B1 | |
| SCHEMBL11977450 | 0.71 | — | — | |
| SCHEMBL9537234 | 0.71 | SIGMAR1 (0.54) | SIGMAR1CHRNB2CHRNA4CYP19A1CYP11B1 | |
| SCHEMBL11977448 | 0.71 | SIGMAR1 (0.54) | SIGMAR1CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL7486260 | 0.69 | SIGMAR1 (0.42) | SIGMAR1CHRNB2CHRNA4CYP19A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109674792-A | The purposes of substituted 5,6- dihydro-isoquinoline simultaneously [3,2- α] isoquinolin -7- derivative | 四川大学 | 2019-04-26 | — | — | CN | claimed |
| WO-2026099533-A1 | TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) WITH GPBP1 INHIBITORS | UNIVERSITAT DE VALÈNCIA (ES) | 2026-05-15 | — | — | WO | disclosed |
| WO-2023154758-A1 | A1H-BENZO[C][1,2]THIADIAZINE-2,2-DIOXIDES BEARING HETEROCYCLIC LINKERS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | GEORGETOWN UNIVERSITY (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20230145442-A1 | CONDENSATION PRODUCT FOR USE IN A METHOD FOR THE TREATMENT OF COVID-19 | IFOM FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2023-05-11 | — | — | US | disclosed |
| CN-113980017-B | Synthesis method of C-13 methyl substituted tetrahydrochysene 13 methyl berberine derivative | 四川大学 | 2023-05-05 | — | — | CN | disclosed |
| EP-4125832-A1 | CONDENSATION PRODUCT FOR USE IN A METHOD FOR THE TREATMENT OF COVID-19 | BASF SE (DE) | 2023-02-08 | — | — | EP | disclosed |
| CN-115551492-A | Condensation products for use in methods of treating COVID-19 | 巴斯夫欧洲公司 | 2022-12-30 | — | — | CN | disclosed |
| WO-2022118016-A2 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-06-09 | — | — | WO | disclosed |
| CN-110049985-B | Heterocyclic sulfones as ROR gamma modulators | 百时美施贵宝公司 | 2022-05-31 | — | — | CN | disclosed |
| WO-2021198332-A1 | CONDENSATION PRODUCT FOR USE IN A METHOD FOR THE TREATMENT OF COVID-19 | BASF SE (DE) | 2021-10-07 | — | — | WO | disclosed |
| US-20020016339-A1 | Piperididinyl and N-amidinopiperidinyl derivatives | KLEIN SCOTT I (US) | 2002-02-07 | — | — | US | disclosed |
| EP-0327239-B1 | 1-carbacephalosporin antibiotics | LILLY CO ELI (US) | 1994-06-22 | — | — | EP | disclosed |
| US-5019571-A | 1-carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1991-05-28 | — | — | US | disclosed |
| US-5011938-A | Antimicrobials | ELI LILLY AND COMPANY (US) | 1991-04-30 | — | — | US | disclosed |
| US-4940718-A | BACTERICIDES | ELI LILLY AND COMPANY (US) | 1990-07-10 | — | — | US | disclosed |
| US-4902707-A | Bicyclic pyrazolidinones, compositions and use | ELI LILLY AND COMPANY (US) | 1990-02-20 | — | — | US | disclosed |
| EP-0327239-A1 | 1-carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1989-08-09 | — | — | EP | disclosed |
| EP-0203722-A1 | Bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-12-03 | — | — | EP | disclosed |
| EP-0202046-A1 | 7-Substituted bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-11-20 | — | — | EP | disclosed |
| CN-86103619-A | The preparation method of the bicyclic pyrazolidinones that 7-replaces | — | 1986-10-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016339-A1 | Piperididinyl and N-amidinopiperidinyl derivatives | F11, F5, TFPI | SIGMAR1 2061/4885CHRNB2 993/4885CHRNA4 396/4885 |
| US-20230145442-A1 | CONDENSATION PRODUCT FOR USE IN A METHOD FOR THE TREATMENT OF COVID-19 | ACE2, SARS1, UBE2M | SIGMAR1 2738/4885CHRNB2 4760/4885CHRNA4 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.